Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.20 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $183.1 million versus the consensus estimate of $191.76 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.